UBS analyst Matthew Taylor initiated Boston Scientific with a Buy rating and $45 price target, calling the stock a Top Buy for Growth/Quality. Taylor said "we think there is room for growth to surprise, based on our detailed analysis of key drivers and acquisitions."
Stifel raised the firm's price target on Boston Scientific to $83 from $70 and keeps a Buy rating on the shares. The firm said the company delivered "solid" Q1 outperformance, underpinned by "important" new product launches. Looking ahead to 2024 and beyond, Stifel believes Boston Scientific could continue outperforming their Loan Repayment Program and the firm's projections.
Check out this morning's top movers from around Wall Street, compiled by The Fly. UP AFTER EARNINGS... To see the rest of the story go to thefly.com. See Story Here